Last reviewed · How we verify

BTT1023 — Competitive Intelligence Brief

BTT1023 (BTT1023) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR2 antagonist monoclonal antibody. Area: Immunology.

phase 2 CCR2 antagonist monoclonal antibody CCR2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BTT1023 (BTT1023) — Biotie Therapies Corp.. BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BTT1023 TARGET BTT1023 Biotie Therapies Corp. phase 2 CCR2 antagonist monoclonal antibody CCR2
ABT-267 ABT-267 AbbVie (prior sponsor, Abbott) phase 3 CCR2 antagonist CCR2 (C-C chemokine receptor type 2)
SR34006 SR34006 Sanofi phase 3 CCR2 antagonist CCR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR2 antagonist monoclonal antibody class)

  1. Biotie Therapies Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BTT1023 — Competitive Intelligence Brief. https://druglandscape.com/ci/btt1023. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: